Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
» Galapagos Announces ISABELA Ph III Study in Idiopathic Pulmonary Fibrosis
Galapagos Announces ISABELA Ph III Study in Idiopathic Pulmonary Fibrosis
Galapagos Announces ISABELA Ph III Study in Idiopathic Pulmonary Fibrosis
Submitted by
admin
on April 12, 2018 - 9:23pm
Source:
CP Wire
News Tags:
Galapagos
GLPG1690
idiopathic pulmonary fibrosis
Headline:
Galapagos Announces ISABELA Ph III Study in Idiopathic Pulmonary Fibrosis
snippet:
GLPG1690 has orphan drug status in US and Europe
Ph II results showed disease stabilization over 12 week period
ISABELA intended to support NDA and MAA in the US and EU
Do Not Allow Advertisers to Use My Personal information